Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators

Journal of Clinical Oncology

Volumn 12, Issue 9, 1994, Pages 1796-1805

  Taylor, Kathryn M ^a   Feldstein, Michael L ^b   Skeel, Roland T ^b   Pandya, Kishan J ^b   Ng, Peggy ^b   Carbone, Paul P ^b  

^a YORK UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE; BEHAVIOR; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION;

EID: 0028130499     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.9.1796     Document Type: Article

References (39)

1. Pocock SJ: Clinical Trials: A Practical Approach. New York, NY, Wiley, 1983
2. Anonymous: NCI mounts campaign to increase numbers of patients in clinical trials Oncology 2:50-57, 1988
3. Kraemer MS, Shapiro SH: Scientific challenges in the application of randomized trials JAMA 252:2739-2745, 1984
4. Louis TA, Shapiro SH: Critical issues in the conduct and interpretation of clinical trials. Annu Rev Public Health 43:25-46, 1983
5. Freidman MA, and Cain DF: National Cancer Institute sponsored cooperative group clinical trials. Cancer 65:2376-2382, 1990
6. Taylor KM, Margolese RG, Soskolne C: Physicians' reasons for not entering eligible patients in a randomized clinical trials of surgery for breast cancer. N Engl J Med 310:1363-1367, 1984
7. Benson AB, Pregler JP, Bean JA, et al: Oncologists' reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study. J Clin Oncol 9:2067-2075, 1991
8. Taylor KM, Shapiro M, Soskolne C, et al: Physician response to informed consent regulations for randomized clinical trials. Cancer 60:1415-1422, 1987
9. Taylor KM, Shapiro M, Skinner HA: Some thoughts on the future of clinical trials groups in cancer. Cancer Treat Rep 71:4343-4345, 1987
10. Fisher B: On clinical trial participation. J Clin Oncol 9:1927-1930, 1991 (editorial)
11. Lacher MJ: Patients and physicians as obstacles to a randomized trial. Semin Oncol 8:424-429, 1981
12. Hoogestraten B (ed): Cancer Research: Impact of the Cooperative Groups. New York, NY, Masson, 1980
13. Begg CB, Zelen M, Carbone PP, et al: Cooperative groups and community hospitals: Measurement of the impact in community hospitals. Cancer 52:1760-1767, 1983
14. Taylor KM, Keiner MJ: Interpreting physician participation in randomized clinical trials: The Physician Orientation Profile. J Health Soc Behav 28:389-400, 1987
15. Taylor KM: Integrating conflicting physician roles: Physician participation in randomized clinical trials. Soc Sci Med 15:217-224, 1992
16. Taylor KM: Physician participation in a randomized clinical trial for ocular melanoma. Ann Opthalmol 24:298-305, 1992
17. SPSS Inc: SPSS/PC + V2.0. Chicago, IL, SPSS Marketing Department, 1988
18. Taylor Kathryn M: Report to the ECOG on the Results of C-0187. Toronto, Canada, University of Toronto, Physician Behaviour Research Unit, March 1990
19. Strauss A, Corbin J: Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Newbury Park, CA, Sage Publications, 1990
20. Begg CB, Engstrom PF: Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 4:972-974, 1986
21. Simon R: Patient heterogeneity in clinical trials. Cancer Treat Rep 64:405-410, 1980
22. Gail MH: Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Cancer Treat Rep 69:1107-1112, 1985
23. Hunter CP, Frelick RW, Feldman AR, et al: Selection factors in clinical trials: Results from the community clinical oncology physicians' log. Cancer Treat Rep 71:559-565, 1987
24. Green SB: Patient heterogeneity and the need for randomized controlled trials. Control Clin Trials 3:189-198, 1982
25. Begg C: Selection of patients for clinical trials. Semin Oncol 15:434-400, 1988
26. Barnett HJM, Sackett D, Taylor DW, et al: Are the results of the extracranial-intracranial bypass trial generalizable? N Engl J Med 316:820-824, 1987
27. Moinpour CM, Feigl P, Metch B, et al: Quality of life: Endpoints in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 81:485-495, 1989
28. Gelber RD, Goldhirsh A: A new endpoint for the assessment of adjuvant therapy for postmenopausal women with operable breast cancer. J Clin Oncol 4:1772-1779, 1986
29. Guyatt GH, Veldhuyzen Van Zanten SJ, Feeney DH, et al: Measuring quality of life in clinical trials: A taxonomy and review. Can Med Assoc J 140:1441-1448, 1989
30. Aaronson NK: Quality of life in clinical trials: metholodologic issues. Control Clin Trials 10:195-208, 1989
31. Byrne M: Cancer chemotherapy and quality of life: Cancer trials should include measures of patients' well-being. Br Med J 304:1523-1524, 1992
32. Tannock I, Boyes M: When is a cancer treatment worthwhile? N Engl J Med 323:989-990, 1990
33. Morgan TM: Planning the duration of accrual and follow-up for clinical trials. J Chron Dis 38:1009-1018, 1985
34. Collins JF: Planning patient recruitment: Fantasy and reality. Stat Med 3:4:56-67, 1984
35. Pocock SJ, Hughes MD: Estimation issues in clinical trials and overviews. Stat Med 9:657-671, 1990
36. Peters TJ, Waterman RH: In Search of Excellence: Lessons from America's Best Run Companies. New York, NY, Harper & Row, 1982
37. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317:141-145, 1987
38. Gifford F: The conflict between randomized clinical trials and the therapeutic obligation. J Med Philos 11:347-366, 1986
39. Bracken MB: Clinical trials and the acceptance of uncertainty. Br Med J 294:1111-1112, 1987